ALREX has a low incidence of elevated IOP1
In clinical studies, patients treated with ALREX presented similar rates of intraocular pressure (IOP) elevation as placebo.1†
- Incidence of clinically significant increases in IOP (≥10 mm Hg) was 1% with ALREX and 1% with placebo in two 6-week safety and efficacy trials in patients with seasonal allergic conjunctivitis (SAC).*
*If ALREX is used for more than 10 days, IOP should be monitored.
†Study design: Two 6-week, double-masked, placebo-controlled, multicenter environmental studies conducted during pollen season in which patients (n=268) with moderate to severe signs and symptoms of SAC bilaterally received ALREX (0.2%) or placebo QID for 42 days. Primary efficacy variables were bulbar conjunctival injection (signs) and ocular itching (symptoms) resolution at Day 14.